Curis Inc (CRIS)
NASDAQ:CRIS

Curis Stock Price & Analysis

1,262 Followers

CRIS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.68 - $5.27
Previous Close$0.84
Volume142.68K
Average Volume (3M)916.58K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$98.69M
Total Debt (Recent Filing)$4.20M
Price to Earnings (P/E)-1.3
Beta2.91
Next EarningsMar 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.64
Shares Outstanding96,398,360
R-Squared0.05
Standard Deviation0.66
10 Day Avg. Volume445,271
30 Day Avg. Volume916,582
Price to Book (P/B)1.73
Price to Sales (P/S)7.76
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside735.62% Upside
Rating ConsensusModerate Buy
Alpha0.03
Number of Analyst Covering2


Financials


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CRIS FAQ

What was Curis’s price range in the past 12 months?
Curis lowest stock price was $0.68 and its highest was $5.27 in the past 12 months.
    What is Curis’s market cap?
    Currently, no data Available
    When is Curis’s upcoming earnings report date?
    Curis’s upcoming earnings report date is Mar 09, 2023 which is in 102 days.
      How were Curis’s earnings last quarter?
      Curis released its earnings results on Nov 09, 2022. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.166 by $0.026.
        Is Curis overvalued?
        According to Wall Street analysts Curis’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Curis pay dividends?
          Curis does not currently pay dividends.
          What is Curis’s EPS estimate?
          Curis’s EPS estimate is -$0.13.
            How many shares outstanding does Curis have?
            Curis has 96,398,360 shares outstanding.
              What happened to Curis’s price movement after its last earnings report?
              Curis reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.166. Following the earnings report the stock price went up 13.889%.
                Which hedge fund is a major shareholder of Curis?
                Among the largest hedge funds holding Curis’s share is Maverick Capital ltd. It holds Curis’s shares valued at 5M.

                  ---

                  Curis Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -83.52%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -74.33%
                  Trailing 12-Months
                  Asset Growth
                  -28.61%
                  Trailing 12-Months
                  The Curis stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Curis Inc

                  Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis